ProCE Banner Activity

Predictive Biomarkers for Targeted Therapies in Advanced NSCLC: ALK and ROS1 Rearrangements, RET and NTRK Fusions, and KRAS G12C and METex14 Mutations

Slideset Download

Download these slides from a live CCO Webinar for an overview of the latest clinical data informing optimal use of ALK, ROS1, RET, NTRK, KRAS G12C, and METex14 biomarkers to guide therapeutic decisions in advanced NSCLC, including updates from recent annual clinical oncology meetings.

Released: June 28, 2021

Expiration: June 27, 2022

Share

Faculty

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Lecia V. Sequist

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts